About US
Contact us
-
UK provides funding support for Covid-19 vaccine programmeThe UK Government has committed to providing £84m in funding and manufacturing support to researchers working on Covid-19 vaccine programme, said Business Secretary Alok Sharma. Of the total funding,2020/5/20
-
AstraZeneca gets breakthrough status for Enhertu to treat NSCLCAstraZeneca and its partner Daiichi Sankyo have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Enhertu (trastuzumab deruxtecan) to treat non-small2020/5/19
-
Phlow secures $354m US contract for drug supply amid Covid-19US-based public benefit drug manufacturing corporation Phlow has received$354m funding from the government to produce essential medicines at risk of shortage amid the Covid-19 pandemic. The contract2020/5/19
-
J&J signs Covid-19 vaccine manufacturing contract with VibalogicsJohnson & Johnson (J&J) has signed a deal with contract development and manufacturing organisation (CDMO) Vibalogics for the manufacture of clinical trial material for a Covid-19 vaccine cand2020/5/18
-
Novartis’ AveXis gets EC conditional approval for ZolgensmaNovartis subsidiary AveXis has received conditional approval from the European Commission (EC) for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA). The approval is for inf2020/5/18
-
Merck's Keytruda thumped SeaGen's Adcetris in a head-to-head trial. How much does it matter?Merck’s Keytruda has taken on the standard of care in classical Hodgkin lymphoma and won. But with a closely watched combination making its way through the clinic,how long will the results be relevan2020/5/15
-
Roche looks for bladder cancer clues in Tecentriq's post-surgery flopWith a phase 3 trial of Tecentriq in high-risk, muscle-invasive bladder cancer patients who had already had surgery, Roche was “hoping to show we could reduce the rate of progression to metastatic di2020/5/15
-
Bristol Myers Squibb in hot water after FDA rebuffs CAR-T therapy on manufacturing concernsAs part of its $74 billion Celgene pickup, Bristol Myers Squibb offered future payouts based on FDA approval for three key pipeline assets. Already in jeopardy after one delay, that payoff looks even2020/5/14
-
Takeda touts blockbuster hopefuls, dials up cost-saving target from Shire dealAs Takeda folds in Shire, the Japanese pharma is looking into the future, which includes waves of blockbuster hopefuls, less debt and more room for cost cuts. The company is looking to launch 12 drug2020/5/14
-
BeiGene's new BTK drug Brukinsa falls short as PD-1 tislelizumab shines in busy quarterBeiGene is squaring off against industry bigwigs with its new BTK inhibitor Brukinsa, and early sales figures showjust how difficult it will be for the Chinese biotech to steal share in the U.S. mark2020/5/13